Search or
𝛼SK
𝛼SKSign in with Google. Opens in new tab
bullish
Eris Lifesciences: Execution Phase Is Key, Downgrade to ADD
Moreover, rh-insulin represents a sizable opportunity for the company over the next few years, with the exit of innovator Novo Nordisk (which will be present only in vials).
What is covered in the Full Insight:
- Introduction to Eris Lifesciences' Execution Phase
- Investment and Growth Strategy
- Market Opportunities: GLP-1 and rh-insulin
- Challenges and Base Business Performance
- Stock Performance and Valuation
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 22-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Taiwan Top 50 ETF Rebalance Preview: Another Inclusion for King Slide
- [Japan M&A] Minebea Matches YAGEO for Shibaura Elec (6957) At ¥6,200. Presses on Early Cashout
- [Japan M&A] Founder, KEPCO, Try ¥2,750 Bain-Led MBO on Rezil (176A). Light Given Growth - Bumpity?
- Shengjing Bank (2066 HK): Another Rural Commercial Bank Delisting
- Quiddity Leaderboard ChiNext & ChiNext 50 Dec25: ~US$900mn Combined Flows One-Way; New Pair Trades
Top Unpaywalled Insights
More »- [IO Technicals 2025/33] China Woes Deepen, Bearish Momentum Grips Iron Ore
- Tradesmen's Collective: Fixing the Trades with Tech, Transparency & Boots-on-the-Ground
- VEON 2Q25: Solid Digital Non-Telco Products Uplift, Kyivstar Listing in Focus
- [IO Technicals 2025/32] Bullish Momentum Builds
- Grab Holdings (GRAB US) - Harvesting Sequentially
Discussions
(Paid Plans Only)
x